Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade C 123.13 -1.39% -1.73
LGND closed down 1.39 percent on Monday, March 25, 2019, on 48 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical LGND trend table...

Date Alert Name Type % Chg
Mar 25 Stochastic Sell Signal Bearish 0.00%
Mar 25 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 25 Overbought Stochastic Strength 0.00%
Mar 22 Overbought Stochastic Strength -1.39%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.68%
Mar 21 Reversal New Highs Setup Bullish Swing Setup -4.68%
Mar 21 Weak + Overbought Other -4.68%
Mar 21 Outside Day Range Expansion -4.68%
Mar 21 Overbought Stochastic Strength -4.68%
Mar 20 MACD Bullish Centerline Cross Bullish -0.46%

Older signals for LGND ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Biotechnology Pain Chemical Compounds Organic Compounds Solid Tumors Alzheimer's Disease Multiple Myeloma Chloroarenes Myelodysplastic Syndrome Clinical Trial Product Phenols Skin And Skin Structure Infections Carboxylic Acids Sarcoma Selective Estrogen Receptor Modulators
Is LGND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 278.62
52 Week Low 98.56
Average Volume 821,307
200-Day Moving Average 181.2163
50-Day Moving Average 118.94
20-Day Moving Average 119.526
10-Day Moving Average 121.64
Average True Range 4.9459
ADX 21.09
+DI 26.6685
-DI 20.5426
Chandelier Exit (Long, 3 ATRs ) 114.7323
Chandelier Exit (Short, 3 ATRs ) 119.1177
Upper Bollinger Band 133.6459
Lower Bollinger Band 105.4061
Percent B (%b) 0.63
BandWidth 23.626491
MACD Line 1.1554
MACD Signal Line -0.1448
MACD Histogram 1.3002
Fundamentals Value
Market Cap 2.59 Billion
Num Shares 21.1 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 300.32
Price-to-Sales 25.74
Price-to-Book 7.36
PEG Ratio 1.53
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 129.09
Resistance 3 (R3) 129.32 127.58 128.09
Resistance 2 (R2) 127.58 126.06 127.46 127.76
Resistance 1 (R1) 125.35 125.12 124.48 125.12 127.43
Pivot Point 123.61 123.61 123.17 123.49 123.61
Support 1 (S1) 121.38 122.09 120.51 121.15 118.83
Support 2 (S2) 119.64 121.15 119.52 118.50
Support 3 (S3) 117.41 119.64 118.17
Support 4 (S4) 117.18